Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Auxilium Pharmaceuticals

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Auxilium Pharmaceuticals (NASDAQ: AUXL), and raised its price target from $28.00 to $30.00.

BofA Merrill Lynch noted, “We view the risk/reward for AUXL shares as positive, as we believe that Xiaflex has significant sales potential for Dupuytren's disease and could be a long-lived asset. Given the advantages of Xiaflex over surgery, we believe that Dupuytren's and follow-on indication Peyronie's could represent $1bn+ market opportunities with limited competition. We also like that Xiaflex is a biologic, which will reduce generic risk exposure and improve long-term revenue and earnings visibility.”

Auxilium Pharmaceuticals closed on Tuesday at $26.94.

Latest Ratings for AUXL

Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014MizuhoDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!